Laninamivir
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Laninamivir
- DrugBank Accession Number
- DB12791
- Background
Laninamivir has been used in trials studying the treatment of Influenza.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 346.3364
Monoisotopic: 346.148849078 - Chemical Formula
- C13H22N4O7
- Synonyms
- Laninamivir
- Laninamivirum
- External IDs
- R 125489
- R-125489
- R125489
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAdenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Laninamivir. Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Laninamivir. Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Laninamivir. Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Laninamivir. Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Laninamivir. - Food Interactions
- Not Available
Categories
- ATC Codes
- J05AH04 — Laninamivir
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acetamides. These are organic compounds with the general formula RNHC(=O)CH3, where R= organyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acid derivatives
- Direct Parent
- Acetamides
- Alternative Parents
- Secondary carboxylic acid amides / Secondary alcohols / Guanidines / 1,2-diols / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Carboximidamides show 5 more
- Substituents
- 1,2-diol / Acetamide / Alcohol / Aliphatic heteromonocyclic compound / Carbonyl group / Carboximidamide / Carboxylic acid / Dialkyl ether / Ether / Guanidine show 15 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- B408IW3GL5
- CAS number
- 203120-17-6
- InChI Key
- QNRRHYPPQFELSF-CNYIRLTGSA-N
- InChI
- InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1
- IUPAC Name
- (2R,3R,4S)-4-carbamimidamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3-acetamido-3,4-dihydro-2H-pyran-6-carboxylic acid
- SMILES
- [H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](OC)[C@H](O)CO
References
- General References
- Not Available
- External Links
- PubChem Compound
- 502272
- PubChem Substance
- 347828969
- ChemSpider
- 439182
- BindingDB
- 50009296
- ChEMBL
- CHEMBL466246
- ZINC
- ZINC000003985629
- PDBe Ligand
- LNV
- Wikipedia
- Laninamivir
- PDB Entries
- 3ti3 / 3ti8 / 3tia / 4hzw / 4mwu / 4mwy / 4qn6
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Flu caused by Influenza / Influenza, Human 1 1 Completed Treatment Flu caused by Influenza 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.12 mg/mL ALOGPS logP -1.9 ALOGPS logP -5.1 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 3.12 Chemaxon pKa (Strongest Basic) 11.65 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 187.22 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 91.23 m3·mol-1 Chemaxon Polarizability 33.07 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-06wc-9213000000-1642909a38b97c723284 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0007-0194000000-242a9409098456b7c929 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0159000000-825777b3c5f8083d94e5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-002g-0294000000-d4600c10541ea68f3153 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004j-2496000000-0dcceb0b44757aa8147a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0r03-1971000000-eddf7ea34a358f7e9553 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004m-2591000000-2f6b75cd108485d61b6c Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 177.14412 predictedDeepCCS 1.0 (2019) [M+H]+ 179.03952 predictedDeepCCS 1.0 (2019) [M+Na]+ 184.81795 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 00:17 / Updated at February 21, 2021 18:53